期刊论文详细信息
Breast Cancer Research
SCR-6852, an oral and highly brain-penetrating estrogen receptor degrader (SERD), effectively shrinks tumors both in intracranial and subcutaneous ER + breast cancer models
Research
Peng Gu1  Yajing Liu2  Ji Zhu2  Jinwen Shan2  Yao Guo2  Linlin Yuan2  Guimei Yang2  Feng Tang3  Liting Xue4  Feng Zhou4  Renhong Tang5 
[1] Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing, China;Simcere Zaiming Pharmaceutical Co., Ltd., Shanghai, China;State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China;Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing, China;State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China;Simcere Zaiming Pharmaceutical Co., Ltd., Shanghai, China;State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China;Simcere Zaiming Pharmaceutical Co., Ltd., Shanghai, China;Jiangsu Simcere Pharmaceutical Co., Ltd., Nanjing, China;
关键词: SCR-6852;    SERD;    Fulvestrant;    Estrogen receptor;    Breast cancer;    Breast cancer brain metastasis;   
DOI  :  10.1186/s13058-023-01695-4
 received in 2023-04-26, accepted in 2023-08-05,  发布年份 2023
来源: Springer
PDF
【 摘 要 】

BackgroundTargeted estrogen receptor degradation has been approved to effectively treat ER + breast cancers. Due to the poor bioavailability of fulvestrant, the first generation of SERD, many efforts were made to develop oral SERDs. With the approval of Elacestrant, oral SERDs demonstrated superior efficacy than fulvestrant. However, due to the poor ability of known SERDs to penetrate the blood–brain barrier (BBB), breast cancer patients with brain metastasis cannot benefit from clinical SERDs.MethodsThe ER inhibitory effects were evaluated on ERα protein degradation, and target genes downregulation. And anti-proliferation activities were further determined in a panel of ER + breast cancer cell lines. The subcutaneous and intracranial ER + tumor models were used to evaluate the efficacy of anti-tumor effects. Brain penetrability was determined in multiple animal species.ResultsSCR-6852 is a novel SERD and currently is under early clinical evaluation. In vitro studies demonstrated that it strongly induced both wildtype and mutant ERα degradation. It potently inhibited cell proliferation in a panel of ER + breast cancer cell lines, including the cell lines containing ESR1 mutations (Y537 and D538). Furthermore, SCR-6852 exhibited pure antagonistic activities on the ERɑ signal axis identified both in vitro and in vivo. Oral administration of SCR-6852 at 10 mg/kg resulted in tumor shrinkage which was superior to Fulvestrant at 250 mg/kg, notably, in the intracranial tumor model, SCR-6852 effectively inhibited tumor growth and significantly prolonged mice survival, which correlated well with the high exposure in brains. In addition to mice, SCR-6852 also exhibited high brain penetrability in rats and dogs.ConclusionsSCR-6852 is a novel SERD with high potency in inducing ERα protein degradation and pure antagonistic activity on ERɑ signaling in vitro and in vivo. Due to the high brain penetrability, SCR-6852 could be used to treat breast patients with brain metastasis.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 预 览 】
附件列表
Files Size Format View
RO202309158779892ZK.pdf 5567KB PDF download
Fig. 2 609KB Image download
Fig. 6 669KB Image download
Fig. 2 103KB Image download
Fig. 5 69KB Image download
Fig. 1 80KB Image download
Fig. 11 593KB Image download
Fig. 1 133KB Image download
Fig. 3 118KB Image download
Fig. 6 632KB Image download
【 图 表 】

Fig. 6

Fig. 3

Fig. 1

Fig. 11

Fig. 1

Fig. 5

Fig. 2

Fig. 6

Fig. 2

【 参考文献 】
  • [1]
  • [2]
  • [3]
  • [4]
  • [5]
  • [6]
  • [7]
  • [8]
  • [9]
  • [10]
  • [11]
  • [12]
  • [13]
  • [14]
  • [15]
  • [16]
  • [17]
  • [18]
  • [19]
  • [20]
  • [21]
  • [22]
  • [23]
  • [24]
  • [25]
  • [26]
  • [27]
  • [28]
  • [29]
  • [30]
  • [31]
  • [32]
  • [33]
  • [34]
  • [35]
  • [36]
  • [37]
  • [38]
  • [39]
  • [40]
  • [41]
  • [42]
  • [43]
  • [44]
  • [45]
  • [46]
  • [47]
  文献评价指标  
  下载次数:2次 浏览次数:0次